<DOC>
	<DOCNO>NCT00830908</DOCNO>
	<brief_summary>The purpose study test whether stimulation vascularization cellular metabolism scalp use HairMax LaserComb produce improvement condition scalp seborrheic dermatitis .</brief_summary>
	<brief_title>HairMax LaserComb Open Label Study Treat Seborrheic Dermatitis</brief_title>
	<detailed_description>This open label pilot study evaluate effect low-level laser light seborrheic dermatitis scalp . Dandruff assessment score scalp seborrheic dermatitis assess baseline monthly evaluation treatment , final assessment end treatment week 12 . The trial involve 10 patient age 18 year old diagnosis seborrheic dermatitis . Patients use LaserComb device three time per week non-consecutive day 12 week . No seborrheic dermatitis product use treatment . The investigator conduct measurement dandruff study visit , measure efficacy . The trial consist 4-5 study visit ( screening/baseline , week 4 , week 8 week 12 ) . Dandruff evaluation adverse event assessment perform visit . Safety analysis assess base report adverse event study .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Seborrheic</mesh_term>
	<criteria>Diagnosis seborrheic dermatitis scalp PGA 2 ( mild ) great baseline TDSS score baseline 2 great , scale inflammation Must agree use nonmedicated shampoos study period ; must refrain use medicate scalp product trial Use topical oral product would affect assessment scalp SD condition , opinion primary investigator , within follow period prior baseline : Medicated shampoo within 2 week baseline Topical scalp medication within 2 week baseline Oral medication affect scalp within 4 week baseline Other medication determine investigator potentially affect assessment SD = washout determine investigator , appropriate know medication property Any current past medical condition , include active dermatitis dermatological condition , might interfere assessment dandruff Patients use medication may increase photosensitivity , thus pose risk undergo LaserComb therapy Patients known adverse reaction , allergy hypersensitivity laser light components/light sensitivity condition Patients receive investigational drug within 30 day prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>seborrheic dermatitis</keyword>
</DOC>